[Surgical treatment of mammary gland diseases].
Explore the source record for details and available documents.
Breast Diseases↗
Biomedical subjects
C Abe
Publications and source records attributed to C Abe.
Effectiveness of immunization with multicomponent vaccines in protection against hemorrhagic pneumonia due to Pseudomonas aeruginosa infection in mink.
The effectiveness of immunizing mink with a new multicomponent vaccine consisting of the common protective antigen (OEP) and toxoids of protease and elastase on experimental as well as epidemic hemorrhagic pneumonia due to Pseudomonas aeruginosa was investigated. This vaccine was compared with a single-component vaccine, consisting of OEP alone, for determination of its effectiveness in immunizing mink. The multicomponent vaccine was significantly more effective than the single-component vaccine. One vaccination with 100 micrograms each of OEP and toxoids of protease and elastase prevented an epidemic in mink of hemorrhagic pneumonia due to P. aeruginosa.
Animals↗
Suppression of type II collagen-induced arthritis by a new isocoumarin, NM-3.
The anti-arthritic effect of NM-3, a new isocoumarin, was examined using a type II collagen-induced arthritis model for human rheumatoid arthritis in DBA/1J mice. NM-3 by oral administration suppressed dose-dependently (2-20 mg/kg/day) not only macroscopic changes such as erythema and swelling of limbs but also histopathologic changes and radiographic changes such as bone lesions. The efficacy of NM-3 was greater than those of disease-modifying anti-rheumatoid drugs (DMARDs), auranofin (40 mg/kg/day) and bucillamine (10 mg/kg/day). NM-3 failed to suppress carageenan-induced edema and to inhibit the activities of inflammation-related enzymes including cyclooxygenase-1 and -2, 5-lipoxygenase and phospholipase A2, suggesting that the mode of anti-arthritic action of NM-3 may be different from those of non-steroidal anti-inflammatory agents (NSAIDs). Since NM-3 inhibits angiogenesis in a mouse dorsal air-sac model, the observed anti-arthritic effect of NM-3 might be partly attributed to the antiangiogenic activity. Thus, NM-3 is a potential orally active therapeutic agent for the treatment of human rheumatoid arthritis.
Animals↗